Research programme: Ebola immunotherapeutics - Regen BioPharma
Latest Information Update: 17 Nov 2014
At a glance
- Originator Regen BioPharma
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Ebola virus infections
Most Recent Events
- 28 Oct 2014 Early research in Ebola virus infections in USA (unspecified route)
- 28 Oct 2014 Regen BioPharma's Ebola immunotherapeutics are available for licensing as of 28 Oct 2014.